Literature DB >> 27927580

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

F Cardoso1, A Costa2, E Senkus3, M Aapro4, F André5, C H Barrios6, J Bergh7, G Bhattacharyya8, L Biganzoli9, M J Cardoso10, L Carey11, D Corneliussen-James12, G Curigliano13, V Dieras14, N El Saghir15, A Eniu16, L Fallowfield17, D Fenech18, P Francis19, K Gelmon20, A Gennari21, N Harbeck22, C Hudis23, B Kaufman24, I Krop25, M Mayer26, H Meijer27, S Mertz28, S Ohno29, O Pagani30, E Papadopoulos31, F Peccatori2, F Penault-Llorca32, M J Piccart33, J Y Pierga34, H Rugo35, L Shockney36, G Sledge37, S Swain38, C Thomssen39, A Tutt40, D Vorobiof41, B Xu42, L Norton43, E Winer25.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27927580     DOI： 10.1016/j.breast.2016.10.001

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


× No keyword cloud information.
  54 in total

1.  ABC4 Consensus: Assessment by a German Group of Experts.

Authors:  Nadia Harbeck; Diana Lüftner; Norbert Marschner; Michael Untch; Doris Augustin; Susanne Briest; Johannes Ettl; Renate Haidinger; Lothar Müller; Volkmar Müller; Eugen Ruckhäberle; Rachel Wuerstlein; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2018-02-15       Impact factor: 2.860

2.  Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

Authors:  Aleix Prat; Jan Christoph Brase; Yuan Cheng; Paolo Nuciforo; Laia Paré; Tomás Pascual; Débora Martínez; Patricia Galván; Maria Vidal; Barbara Adamo; Gabriel N Hortobagyi; José Baselga; Eva Ciruelos
Journal:  Oncologist       Date:  2019-01-24

3.  Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.

Authors:  Ginés Luengo-Gil; Elena García-Martínez; Asunción Chaves-Benito; Pablo Conesa-Zamora; Esther Navarro-Manzano; Enrique González-Billalabeitia; Elisa García-Garre; Alberto Martínez-Carrasco; Vicente Vicente; Francisco Ayala de la Peña
Journal:  Cell Oncol (Dordr)       Date:  2019-05-21       Impact factor: 6.730

4.  Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.

Authors:  Mark Robson; Kathryn J Ruddy; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Wei Li; Nadine Tung; Anne Armstrong; Suzette Delaloge; Wendy Bannister; Carsten Goessl; Arnold Degboe; Robert Hettle; Pierfranco Conte
Journal:  Eur J Cancer       Date:  2019-08-22       Impact factor: 9.162

5.  U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer.

Authors:  A P Nunes; C Liang; W J Gradishar; T Dalvi; J Lewis; N Jones; E Green; M Doherty; J D Seeger
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

6.  The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer.

Authors:  Achim Wöckel; Ute-Susann Albert; Wolfgang Janni; Anton Scharl; Rolf Kreienberg; Tanja Stüber
Journal:  Dtsch Arztebl Int       Date:  2018-05-04       Impact factor: 5.594

Review 7.  Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.

Authors:  Virginia G Kaklamani; Andrea L Richardson; Carlos L Arteaga
Journal:  Oncologist       Date:  2019-01-16

8.  Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.

Authors:  Melanie Royce; Thomas Bachelot; Cristian Villanueva; Mustafa Özgüroglu; Sergio J Azevedo; Felipe Melo Cruz; Marc Debled; Roberto Hegg; Tatsuya Toyama; Carla Falkson; Joon Jeong; Vichien Srimuninnimit; William J Gradishar; Christina Arce; Antonia Ridolfi; Chinjune Lin; Fatima Cardoso
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

9.  Isolated thoracic perfusion in lung metastases from breast cancer: a retrospective observational study.

Authors:  Stefano Guadagni; Karl Aigner; Odisseas Zoras; Francesco Masedu; Giammaria Fiorentini; Enrico Ricevuto; Marcello Deraco; Marco Clementi
Journal:  Updates Surg       Date:  2018-12-12

10.  Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.

Authors:  Dejan Juric; Filip Janku; Jordi Rodón; Howard A Burris; Ingrid A Mayer; Martin Schuler; Ruth Seggewiss-Bernhardt; Marta Gil-Martin; Mark R Middleton; José Baselga; Douglas Bootle; David Demanse; Lars Blumenstein; Karl Schumacher; Alan Huang; Cornelia Quadt; Hope S Rugo
Journal:  JAMA Oncol       Date:  2019-02-14       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.